Video

Our team behind the scenes at SXSW | Opening by Joanna Shields, BenevolentAI CEO

In our 5 part series filmed at SXSW, our team showcased how AI can be used to better understand the underlying causes of disease, and redefine the way new medicines are brought to patients.

In this first video, our CEO, Joanna Shields, introduces the Benevolent team and our vision. We brought our Benevolent Team to Texas to share our collective vision of using the power of technology to solve something that truly matters to the world. For us, this means tackling the most challenging and devastating diseases that currently have no cure. We believe our efforts can and will change outcomes for patients.

There are an estimated 9,000 untreated diseases in the world and 300 million people suffering from rare diseases. Developing a treatment and getting it to market takes 10-15 years and costs more than $2.5 billion. After all that, the top ten selling drugs in the market today only work for 30-50% of patients.

Why? Because biology is complicated. The underlying molecular mechanisms, pathways and biological processes specific to a patient needs to be fully understood to effectively diagnose a disease and develop a medicine to treat it.

Humans are limited by the amount of information they can absorb and process. Against a backdrop of >10,000 new scientific papers published daily, and the millions of patents, chemical databases, clinical trials and countless other data sources, it’s almost impossible for scientists to leverage all the existing information to make new discoveries.  While this deluge of data represents a limitation of human comprehension, it lends itself perfectly to machine learning.  

AI can help us uncover relationships between diseases and symptoms, drugs and their effect, the patients that will best respond to treatment and much more. At BenevolentAI, we believe that unconventional thinking combined with purposeful technology can truly make an impact on humanity.  

Watch our team share this example of how we work to do exactly that.

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021